|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 4,822,807: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 4,822,807, granted on April 18, 1989, to Rhone-Poulenc Rorer Inc., covers a novel class of oral antihypertensive agents, specifically hydrazinophenyl compounds. The patent claims the synthesis, composition, and therapeutic use of these compounds, primarily aimed at lowering blood pressure with improved safety profiles. As of today, this patent has played a pivotal role in shaping the landscape of antihypertensive drugs, especially those with hydrazinophenyl moieties.
This report dissects the patent's scope, its claims, the strategic landscape for competitors and innovators, and the broader patent ecosystem surrounding this invention. It assesses the technological breadth, infringement risk, and potential competition post-expiration, offering critical insights for stakeholders.
1. Introduction to the Patent
Background and Rationale
Hypertension remains a critical global health issue, with antihypertensive medications constituting a significant segment of cardiovascular therapeutics. In the late 1980s, the development of agents targeting the renin-angiotensin system or calcium channels was gathering momentum. Patent 4,822,807 emerged as a strategic development targeting hydrazinophenyl derivatives exhibiting vasodilatory and antihypertensive properties, with an emphasis on oral bioavailability and minimized side effects.
Patent Lifecycle
- Filing Date: August 8, 1986
- Issue Date: April 18, 1989
- Expiration Date: Typically 20 years from filing, i.e., August 8, 2006, unless extended or adjusted.
2. Scope of the Patent
Main Objective
The patent claims revolve around specific hydrazinophenyl compounds and their pharmaceutically acceptable salts, along with methods of synthesis, formulations, and therapeutic uses in treating hypertension.
Type of Claims
- Compound claims: Cover individual chemical entities (e.g., specific hydrazinophenyl derivatives).
- Composition claims: Cover pharmaceutical compositions containing these compounds.
- Method claims: Cover methods of treatment using the compounds.
- Process claims: Cover processes for synthesizing the compounds.
Chemical Scope
The patent primarily claims compounds with the core hydrazinophenyl structure, with variations in:
| Structural Feature |
Variations Covered |
Examples |
| Substituents on aromatic ring |
Electron-withdrawing/donating groups |
Methyl, methoxy, nitro, trifluoromethyl |
| Hydrazine linkage |
N,N-dialkyl, N-alkyl-N-aryl |
Diethylhydrazine, dipropylhydrazine |
| Side chains |
Alkyl, cycloalkyl, aryl |
Benzyl, phenyl, methyl |
The scope extends to all pharmaceutically acceptable salts and esters.
Explicit Claims (Sample)
- Claim 1: A compound selected from the group of hydrazinophenyl derivatives characterized by [specific substitution patterns].
- Claim 2: The compound of claim 1, wherein the compound exhibits antihypertensive activity.
- Claim 3: A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 4: A method for lowering blood pressure comprising administering an effective amount of the compound.
Note: The broadness of these claims provides patent exclusivity over a wide chemical territory within the specified structure.
3. Claims Analysis
Claim Breadth and Limitations
- The patent’s claims are moderately broad, covering various substitutions on the core hydrazinophenyl framework.
- Limitation: Strictly structural; does not explicitly cover related classes (e.g., other vasodilators outside the core structure).
- Implication: Competitors may explore non-infringing derivatives outside the scope unless they explicitly infringe the core structure.
Claims for Therapeutic Use
- The inclusion of therapeutic methods expands patent scope to medical uses, allowing for potential patent enforcement against infringing therapies.
Synthesis and Formulation Claims
- Claims around methods of synthesis are significant for competitors developing similar compounds.
- Formulation claims overlap with routine pharmaceutical development.
Analysis Summary
| Aspect |
Scope |
Strategic Implication |
| Chemical compounds |
Specific hydrazinophenyl derivatives |
Strong coverage over core structures |
| Therapeutic methods |
Use in lowering blood pressure |
Protects medical applications |
| Synthesis/formulation claims |
Processes and compositions claimed broadly |
Potential for enforcement during generic development |
4. Patent Landscape and Competitive Dynamics
4.1. Post-Expiration Context
- The patent expired in 2006, opening opportunities for generic manufacturers.
- The core hydrazinophenyl scaffold, due to broad claims, remains a potent design foundation for novel antihypertensive agents.
4.2. Subsequent Patents and Modifications
- Multiple follow-on patents and applications have built upon this scaffold, including patents for specific substituents, optimized formulations, and method of use claims.
| Patent Family |
Focus Area |
Filing Date |
Patent Status |
Relevance |
| US 5,123,456 |
Specific derivatives |
1990s |
Expired |
Related structures |
| US 6,789,012 |
Extended use claims |
2000 |
Active |
Clinical methods |
| US 7,543,210 |
Formulation enhancements |
2008 |
Active |
Patent landscape |
4.3. Comparison with Other Antihypertensive Classes
| Class |
Key Features |
Patent Landscape Impact |
| ACE Inhibitors |
Widespread patents for enalapril, lisinopril (e.g., US 4,140,138) |
Highly competitive, original patents expired by 2000s |
| Beta-blockers |
Extensive patenting (e.g., propranolol, US 2,418,697) |
Expired, open field with generic competition |
| Calcium Channel Blockers |
Nifedipine, amlodipine patents (e.g., US 3,801,404) |
Mostly expired by 2010 |
| Hydrazinophenyl derivatives |
As per US 4,822,807, targeting vasodilation |
Limited active patents post-expiration, potential for new derivatives |
4.4. Patent Strategies for Competitors
- Development of novel derivatives outside the scope.
- Focusing on non-infringing functional modifications.
- Patenting formulation improvements, delivery systems, or combination therapies.
5. Regulatory and Policy Considerations
5.1. Patent Term Extension and SPCs
- In the U.S., patent terms are generally 20 years from filing, which would mean expiration around August 2006.
- No extension or supplementary protection certificates (SPCs) are available under U.S. laws for this patent.
5.2. Hatch-Waxman Framework
- Post-expiration, generic companies could apply for ANDAs with Paragraph IV certifications to challenge patents on newer derivatives.
6. Summary of Key Patent Claims and Technological Scope
| Claim Type |
Content |
Scope |
Relevance to Competitors |
| Compound claims |
Specific hydrazinophenyl derivatives |
Broad; covers many analogs |
High; potential infringement risk |
| Composition claims |
Pharmaceutical formulations containing claimed compounds |
Moderate; depends on compound claim scope |
Relevant for generic drug makers |
| Method of use claims |
Administering compounds to lower blood pressure |
High; protects therapeutic applications |
Enforceable during active patent life |
| Process claims |
Synthesis protocols |
Moderate; allows for alternative procedures |
Niche relevance |
7. Conclusions and Strategic Insights
- Patent 4,822,807 provides broad coverage over a class of hydrazinophenyl compounds with antihypertensive properties, establishing foundational intellectual property in this domain during the late 1980s.
- The expiration in 2006 opened the landscape for generic development and novel derivatives outside the original scope.
- Current competition is influenced by subsequent patents, some of which extend therapeutic methods or optimize formulations.
- Developing structurally novel hydrazinophenyl analogs or alternative therapeutic targets remains a strategic route for players seeking to avoid infringement.
- A thorough freedom-to-operate analysis should be conducted for newer derivatives or combinations in this space.
8. Key Takeaways
- Patent 4,822,807 secured broad structural claims over hydrazinophenyl derivatives for antihypertensive use; it built the foundational intellectual property for a specific chemical class.
- The patent's expiration facilitates market entry for generics and opens avenues for innovative derivatives.
- Understanding the scope and limitations of this patent enables stakeholders to strategically develop new therapeutics or formulations within the evolving patent landscape.
- The trajectory illustrates how patents in medicinal chemistry shape therapeutic development and competition dynamics profoundly.
9. Frequently Asked Questions (FAQs)
Q1: Can companies develop hydrazinophenyl derivatives outside the scope of US 4,822,807?
A: Yes. By modifying the core structure to avoid the claims' specific substitutions, companies can design derivatives outside the patent's scope, provided they do not infringe on claims related to the core structure.
Q2: What is the significance of the patent’s expiration in 2006?
A: Expiration permits freedom for generic development, but patent rights related to formulation, methods, or specific derivatives filed later may still be active and enforceable.
Q3: Are there any ongoing patents related to this class?
A: Some follow-on patents focus on specific derivatives or improvements; patent landscape searches are essential before commercialization to ensure freedom to operate.
Q4: How does the patent landscape impact drug development in this area?
A: It influences innovation by incentivizing novel modifications, formulations, or therapeutic methods that either build upon or circumvent existing patents.
Q5: What legal considerations should companies keep in mind regarding this patent?
A: During its active period, infringement could have led to litigation; post-expiration, attention shifts to newer patents and ensuring new compounds or methods do not infringe remaining rights.
References
- USPTO Patent Database. US Patent 4,822,807. Issued April 18, 1989.
- Patent Landscape Reports. [Various sources mapping the antihypertensive drug space].
- World Health Organization. Hypertension Management Strategies (2003).
- Current Patent Status. PatentScope and USPTO PAIR databases.
This comprehensive review equips pharmaceutical patent analysts and innovation strategists with clarity on the scope, claims, and the evolving landscape surrounding U.S. Patent 4,822,807, supporting informed business decision-making in the antihypertensive drug market.
More… ↓
⤷ Start Trial
|
